Clinical trials: Malignant Melanomas
Melanoma
A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients
SHR6390 is a small molecular,oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in Chinese advanced melanoma patients by using a…
- Trial name
- NCT02671513
- Testing
- SHR6390
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Cancer, Solid Tumor
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors.
- Conditions
- Cancer, Solid Tumor, Melanoma, Carcinoma
- Trial name
- NCT05708950
- Testing
- KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kineta Inc.
Metastatic Melanoma, Malignant Metastatic Melanoma
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective, and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.
- Conditions
- Metastatic Melanoma, Malignant Metastatic Melanoma, Advanced Melanoma, Melanoma
- Trial name
- NCT01212276
- Testing
- MORAb-028
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Morphotek
Melanoma, Melanoma, Skin
AI-based Medical Device Validation for Early Melanoma Detection
The goal of this observational study is to learn if a computer-aided diagnosis (CAD) system can help identify skin cancer (cutaneous melanoma).
- Trial name
- LEGIT_MC_EVCDA (NCT06221397)
- Testing
- AI-based Computer-Aided Diagnosis (CAD) Software for Skin Lesion Analysis.
- Where
- Spain
- Volunteers
- 105 people
- Sponsor
- AI Labs Group S.L
Uveal Melanoma, Choroid Neoplasm
Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma
The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal…
- Trial name
- NCT02771340
- Testing
- ICON-1
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Iconic Therapeutics, Inc.
Melanoma
ATL001 in Patients With Metastatic or Recurrent Melanoma
This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterize the safety and clinical activity of ATL001, autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with…
- Trial name
- NCT03997474
- Testing
- ATL001, Checkpoint Inhibitor
- Where
- 10 sites in Spain, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Achilles Therapeutics UK Limited
Melanoma
International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma
An International Multicenter Open-label Randomized Trial of the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) as Monotherapy in Patients with Unresectable/Metastatic Melanoma.
- Trial name
- MIRACULUM (NCT03269565)
- Testing
- BCD-100
- Where
- 9 sites in Russia
- Volunteers
- 126 people
- Sponsor
- Biocad
Melanoma
Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy
The purpose of this study is to describe the safety and effectiveness of nivolumab treatment, either in monotherapy or in combination with ipilimumab, overall and according to various subgroups of interest, in participants with…
- Trial name
- NICO (NCT02990611)
- Where
- Germany
- Volunteers
- 1,087 people
- Sponsor
- Bristol-Myers Squibb
Melanoma, Adjuvant
Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection
The purpose of this Treatment Plan is to allow access to trametinib and dabrafenib for eligible high-risk BRAF mutation-positive patients in the adjuvant treatment of melanoma after surgical resection.
- Trial name
- NCT04544202
- Testing
- Dabrafenib and Trametinib, Dabrafenib, Trametinib
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Malignant Melanoma
Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma
Thermotherapy is a technology aiming at destroying tissue, for example tumor tissue. Immunostimulating Interstitial Laser Thermotherpy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue…
- Trial name
- NCT02650492
- Testing
- Immunostimulating Interstitial Laser Thermotherapy
- Where
- Sweden
- Volunteers
- 2 people
- Sponsor
- Clinical Laserthermia Systems AB
Brain Metastases
An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis
This is a multicenter, randomized open-label Phase 2 study to assess the safety, efficacy and pharmacokinetic (PK) of 2 dosing regimens of encorafenib + binimetinib combination in patients with BRAFV600-mutant melanoma with brain…
- Trial name
- POLARIS (NCT03911869)
- Testing
- encorafenib, binimetinib
- Where
- 25 sites in United States, Argentina and 3 more
- Volunteers
- 13 people
- Sponsor
- Pfizer
Cholangiocarcinoma, Chondrosarcoma
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors…
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Trial name
- NCT04521686
- Testing
- LY3410738, Gemcitabine, Cisplatin
- Where
- 33 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Skin Lesion, Melanoma (Skin)
Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging)
The goal of the SFI is to provide non-invasive information about tissue remodeling occurring during melanocytic transition and atypia development in the skin
- Conditions
- Skin Lesion, Melanoma (Skin), Mole
- Trial name
- NCT03535077
- Testing
- Diagnostic Test
- Where
- 6 sites in United States
- Volunteers
- 186 people
- Sponsor
- Orlucent, Inc
Advanced Solid Tumors, Melanoma
Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors
A multicenter, open-label, phase 1b/2 study to evaluate the safety and efficacy of AK104, a PD-1 and CTLA-4 bispecific antibody, in selected advanced solid tumors.
- Trial name
- NCT04172454
- Testing
- AK104
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Akeso
Solid Tumors
A Study of DF6002 Alone and in Combination With Nivolumab
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
- Trial name
- NCT04423029
- Testing
- DF6002, Nivolumab
- Where
- 32 sites in United States, Australia and 2 more
- Volunteers
- 170 people
- Sponsor
- Dragonfly Therapeutics
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Non Small Cell Lung Cancer, Microbiome
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
The goal of the project is to develop and validate the BioForte technology. Its main functionality should be to in silico determine candidates for novel microbiome-based therapeutics and diagnostics.
- Conditions
- Non Small Cell Lung Cancer, Microbiome, Metagenome, Immunotherapy
- Trial name
- NCT04136470
- Testing
- Collection of stool, blood (PBMC) and biopsy (FFPE)
- Where
- 10 sites in Poland
- Volunteers
- 130 people
- Sponsor
- Ardigen
Melanoma
KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
This is a phase 1b/2, open label study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of KD6001 in combination with toripalimab in patients with advanced melanoma.
- Trial name
- NCT05723432
- Testing
- KD6001, Toripalimab
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Shanghai Kanda Biotechnology Co., Ltd.
Urothelial Carcinoma, Renal Cell Carcinoma
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
The objective of this study is to assess the overall response rate, evaluate the antitumor activity, and characterize the safety and tolerability of BGB-A445 alone or in combination with tislelizumab in participants With Advanced…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma
- Trial name
- NCT05661955
- Testing
- BGB-A445, Tislelizumab
- Where
- 18 sites in China
- Volunteers
- 113 people
- Sponsor
- BeiGene
Melanoma
Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
This study aims to compare real-world effectiveness of BRAF/MEK inhibitors in BRAF-mutant metastatic melanoma patients in the United States by line of therapy.
- Trial name
- OCEANMIST (NCT05260684)
- Testing
- Encorafenib, Binimetinib, Vemurafenib
- Where
- United States
- Volunteers
- 716 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.